1 week Ago By Defense World Staff
Norges Bank purchased a new position in shares of Pulmonx Co. (NASDAQ:LUNG – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 151,200 shares of the company’s stock, valued at approximately $1,027,000.
Norges Bank owned 0.38% of Pulmonx as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company.
272 Capital LP acquired a new position in shares of Pulmonx in the 3rd quarter valued at $48,000. R Squared Ltd purchased a new position in Pulmonx during the 4th quarter worth $46,000. SG Americas Securities LLC increased its stake in Pulmonx by 27.
0% in the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after purchasing an additional 3,310 shares during the period. American Century Companies Inc.
increased its stake in Pulmonx by 8.8% in the fourth quarter. American Century Companies Inc.
now owns 34,738 shares of the company’s stock valued at $236,000 after purchasing an additional 2,810 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Pulmonx by 4.9% in the fourth quarter.
Rhumbline Advisers now owns 53,503 shares of the company’s stock valued at $363,000 after buying an additional 2,488 shares during the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.
Insider ActivityIn other Pulmonx news, CEO Steven S. Williamson sold 27,689 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.
14, for a total transaction of $197,699.46. Following the sale, the chief executive officer now directly owns 194,342 shares in the company, valued at approximately $1,387,601.
88. The trade was a 12.47 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Glendon E. French III sold 55,453 shares of the company’s stock in a transaction on Thursday, February 20th.
The shares were sold at an average price of $8.28, for a total value of $459,150.84.
Following the completion of the sale, the director now directly owns 1,011,974 shares in the company, valued at $8,379,144.72. This trade represents a 5.
20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 147,986 shares of company stock worth $1,143,673 in the last 90 days.
5.70% of the stock is currently owned by corporate insiders. Pulmonx Stock PerformanceNASDAQ LUNG opened at $5.
25 on Friday. The stock has a market capitalization of $208.93 million, a price-to-earnings ratio of -3.
65 and a beta of 0.61. The business’s 50 day moving average is $7.
20 and its two-hundred day moving average is $6.78. Pulmonx Co.
has a 12-month low of $4.89 and a 12-month high of $10.01.
The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.
40. Pulmonx (NASDAQ:LUNG – Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.
33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12.
The firm had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million.
Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%.
Research analysts expect that Pulmonx Co. will post -1.55 EPS for the current year.
Wall Street Analyst Weigh InLUNG has been the topic of a number of research reports. Citigroup began coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating on the stock.
Jefferies Financial Group initiated coverage on Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Morgan Stanley began coverage on Pulmonx in a research note on Monday, March 10th.
They set an “equal weight” rating for the company. Finally, D. Boral Capital began coverage on Pulmonx in a report on Monday, March 10th.
They set a “buy” rating and a $17.00 price target for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock.
According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.75.
Check Out Our Latest Report on PulmonxPulmonx Company Profile (Free Report)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.Recommended StoriesFive stocks we like better than PulmonxWhat is the MACD Indicator and How to Use it in Your TradingRobinhood Strategies Could Be a Game-Changer for Young InvestorsOptions Trading – Understanding Strike PriceAre These 3 Retail Stocks Oversold or Really in Trouble?Health Care Stocks Explained: Why You Might Want to InvestIONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
